Welcome to our dedicated page for Zai Lab SEC filings (Ticker: ZLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zai Lab Limited (ZLAB) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures related to its American Depositary Shares listed on the Nasdaq Global Market. Zai Lab is a research-based, commercial-stage biopharmaceutical company based in China and the United States, focused on oncology, immunology, neuroscience, and infectious disease. Its SEC filings offer detailed information on financial performance, risk factors, capital structure, and key corporate agreements.
Through this page, users can review Zai Lab’s current reports on Form 8-K, which have covered topics such as quarterly financial results and the entry into a material definitive agreement for a renminbi-denominated revolving credit facility to support working capital needs in mainland China. These filings also describe how certain information, including earnings press releases furnished as exhibits, is treated for purposes of the Securities Exchange Act of 1934.
In addition to 8-Ks, investors can use this page as a starting point to locate Zai Lab’s annual and other periodic reports filed with the SEC, which discuss its dual-engine strategy, commercial portfolio in China, and global research and development programs. For a biopharmaceutical company like Zai Lab, these documents are important for understanding product revenue sources, R&D investment, licensing arrangements for medicines such as VYVGART, NUZYRA, ZEJULA, AUGTYRO, and COBENFY, and the financial implications of its pipeline.
Stock Titan enhances the raw filing data with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly identify items such as new credit facilities, changes in operations, or significant clinical and commercial milestones referenced in the filings. Real-time updates from EDGAR, combined with organized access to forms including 8-K and other SEC documents, allow users to monitor ZLAB’s regulatory reporting and corporate actions efficiently.
Zai Lab Limited (NASDAQ: ZLAB) filed a Form 144 indicating that insider Ying Du plans to sell 7,072 American Depositary Shares (ADS) on 02 July 2025 through Fidelity Brokerage Services. The proposed transaction is valued at US$249,143.73, representing roughly 0.0015 % of the company’s 486.9 million ADS outstanding, and stems from the vesting of restricted stock on 01 July 2025.
The filing also discloses that the same insider has already sold 235,729 ADS between 02 April 2025 and 30 June 2025, generating an estimated US$7.1 million in gross proceeds. These prior sales were executed in eight tranches ranging from 2,945–50,000 ADS each.
Although the absolute dollar value of the individual sale is modest relative to Zai Lab’s market capitalization, the cumulative selling pattern may be interpreted by some investors as a signal of insider profit-taking. No new operational, earnings or strategic information is provided in this filing; the document is strictly a regulatory notice satisfying Rule 144 requirements.
Zai Lab (NASDAQ:ZLAB) filed a Form 4 revealing that Chief Legal Officer Edmondson Frazor Titus III’s 14,600 RSUs vested on 25 Jun 2025, converting into the same number of ADSs.
To cover withholding taxes, he sold 5,877 ADSs on 26 Jun 2025 at $36.132 (≈ $213 k), coded “S”. Post-transaction, his direct stake stands at 44,975 ADSs, each ADS representing ten ordinary shares.
The sale, while automatic under a Rule 10b5-1 plan, equals roughly 12 % of his pre-sale position, crossing the 5 % materiality threshold and offering investors a governance data-point rather than a directional signal.
Key Form 4 details for Zai Lab Ltd (ZLAB): On 25 June 2025, Chairperson & CEO Ying Du received 58,800 American Depositary Shares (ADS) upon the vesting of previously granted Restricted Share Units (RSUs). Each ADS represents ten ordinary shares. The conversion was reported under transaction code “M,” indicating a delivery of shares without cash consideration.
On 26 June 2025 the executive executed an automatic sale (code “S”) of 23,669 ADS at US $36.132 per ADS to satisfy tax-withholding obligations triggered by the vesting event. After both transactions, Du’s direct beneficial ownership stands at 514,982 ADS.
Net effect: the CEO’s holdings increased by 35,131 ADS relative to the amount immediately prior to the RSU vesting, reinforcing management’s equity alignment while acknowledging routine tax-related disposals. No derivative positions remain in connection with this RSU tranche.
The RSUs follow a four-year vesting schedule that began on 25 June 2023; future anniversaries may lead to similar withhold-to-cover sales. Investors typically view net ownership increases as a positive governance signal, although periodic sales could add modest near-term share supply.
Zai Lab CFO Chen Yajing reported multiple transactions on Form 4 involving American Depositary Shares (ADS) on June 25-26, 2025:
- Acquired 6,250 ADSs through the vesting of Restricted Share Units (RSUs) on June 25
- Subsequently sold 2,675 ADSs at $36.132 per share on June 26 for tax coverage
- Following these transactions, directly owns 21,004 ADSs
The RSUs were granted under a four-year vesting schedule beginning June 25, 2023, with equal annual installments. Each ADS represents ten ordinary shares of the company. The automatic sale of shares was specifically conducted to cover tax obligations from the RSU vesting. The transactions were reported through an attorney-in-fact on June 27, 2025.